Article Details

Fidanacogene Elaparvovec Shows Strong Results in Open-Label Phase 3 Study

Retrieved on: 2024-11-06 16:29:56

Tags for this article:

Click the tags to see associated articles and topics

Fidanacogene Elaparvovec Shows Strong Results in Open-Label Phase 3 Study. View article details on hiswai:

Excerpt

The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.

Article found on: www.ajmc.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up